Strong Buy Rating for Collegium Pharmaceutical Driven by Robust 2025 Performance and Growth Potential

Analyst Serge Belanger of Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report), retaining the price target of $46.00.

Serge Belanger has given his Buy rating due to a combination of factors including Collegium Pharmaceutical’s strong start to 2025, marked by a first-quarter revenue of $177.8 million, which exceeded market expectations. This performance was driven by the success of JornayPM and the pain portfolio, particularly Nucynta.
Belanger anticipates further growth for JornayPM throughout 2025 and into 2026, supported by increased investments such as an expanded sales force and enhanced advertising efforts. Additionally, the company’s focus on business development and potential acquisition of a CNS product to leverage the expanded sales force further supports the Buy rating. The valuation is considered favorable, as it does not fully reflect the company’s growth potential, profitability, and successful track record in acquiring and integrating valuable assets.

According to TipRanks, Belanger is a 3-star analyst with an average return of 1.7% and a 41.54% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Cytokinetics, Esperion, and Evolus.